|
Post by iamaverb on Jan 22, 2018 17:28:03 GMT
How 'bout them CRISPR companies? Lot's of M&A in the Biotechs and some with ramifications for the CRISPR gene editors especially with Editas and Juno. More @ CRISPR Investor on facebook. CRSP has risen 100% in less than a month
|
|
|
Post by iamaverb on Apr 14, 2018 16:48:09 GMT
The oral arguments for the CRISPR patent interference appeal will be held in DC at the end of the month, and I intend to be in the gallery. Time will tell if this case turns out to be the single most important patent case in history.
|
|
|
Post by selluwud on Apr 17, 2018 14:45:26 GMT
The oral arguments for the CRISPR patent interference appeal will be held in DC at the end of the month, and I intend to be in the gallery. Time will tell if this case turns out to be the single most important patent case in history. Please keep us up to date. Even though I haven't invested here yet, I have been tracking the two main players. Edit has more than doubled and CRSPR has more than tripled. Why the big difference?
|
|
|
Post by iamaverb on Jul 3, 2018 13:23:54 GMT
The oral arguments for the CRISPR patent interference appeal will be held in DC at the end of the month, and I intend to be in the gallery. Time will tell if this case turns out to be the single most important patent case in history. Please keep us up to date. Even though I haven't invested here yet, I have been tracking the two main players. Edit has more than doubled and CRSPR has more than tripled. Why the big difference? CRSP announced their IND and tripled, but the FDA placed their trials on hold and the share price has fallen to a double. Watch EDIT, as they are within their announced window for starting their trials to treat blindness.
|
|
|
Post by selluwud on Jul 3, 2018 14:28:56 GMT
Please keep us up to date. Even though I haven't invested here yet, I have been tracking the two main players. Edit has more than doubled and CRSPR has more than tripled. Why the big difference? CRSP announced their IND and tripled, but the FDA placed their trials on hold and the share price has fallen to a double. Watch EDIT, as they are within their announced window for starting their trials to treat blindness. I bought a few shares back in the beginning of May and have stayed green ever since. Lots of second guessing by the scientific community every time you turn around, but it seems to not be a lingering factor so far.
|
|
|
Post by selluwud on Jul 26, 2018 14:13:39 GMT
Verb, what is your take on the latest CRSPR controversy? The unintended modifications happening outside of the target area of manipulation? I sold my holdings on the fear of a market retreat until this technique is proven safe. I made some profit when I sold but it is still falling.
|
|
|
Post by selluwud on Mar 3, 2019 13:16:56 GMT
|
|
|
Post by selluwud on Nov 19, 2019 15:51:22 GMT
|
|
|
Post by lcd on Nov 19, 2019 16:31:07 GMT
I own EDIT, which has not done nearly as well as CRSP over the past 6 months, but it is up over 13% on the data release.
|
|
|
Post by selluwud on Feb 7, 2020 15:39:13 GMT
I added an IPO issue yesterday "BEAM" and got in at 18.75. Dr. Feng Zhang, Co-Founder, also co-founder of EDIT. Hoping this bio-technology method has a promising future.
|
|
|
Post by JHam on Feb 8, 2020 2:28:01 GMT
I added an IPO issue yesterday "BEAM" and got in at 18.75. Dr. Feng Zhang, Co-Founder, also co-founder of EDIT. Hoping this bio-technology method has a promising future. Nice, well done.
|
|
|
Post by iamaverb on Feb 12, 2020 19:07:23 GMT
I added an IPO issue yesterday "BEAM" and got in at 18.75. Dr. Feng Zhang, Co-Founder, also co-founder of EDIT. Hoping this bio-technology method has a promising future. Nice, well done. I should have bought more Beam and will if it backs down some. Editas is resembling ACTC/Ocata more and more with their missed timelines.
|
|
|
Post by lcd on Feb 12, 2020 19:41:12 GMT
I should have bought more Beam and will if it backs down some. Editas is resembling ACTC/Ocata more and more with their missed timelines. I sold all my shares in $EDIT on a recent spike. Too many other stocks out there moving better.
|
|
|
Post by selluwud on Mar 4, 2020 16:50:43 GMT
|
|
|
Post by iamaverb on Mar 5, 2020 17:21:35 GMT
Editas is up 15% since yesterday and currently has 8,654,074 shares sold short, so expect the shorts are covering their positions. Editas also has an agreement with Bluerock Therapeutics to use their ISPC cells. From the press release: "Genome editing and cell therapy technologies are rapidly advancing with the potential to significantly impact the future of medicine. The combination of these two technologies creates a powerful platform for the discovery of new, off-the-shelf engineered cell medicines with transformative potential. As part of the research collaboration, the companies will collaborate to create novel, allogeneic pluripotent stem cell (PSC) lines utilizing a combination of Editas Medicine’s CRISPR genome editing technology and BlueRock’s induced pluripotent stem cell (iPSC) platform. The research collaboration will further enable the creation of engineered, differentiated, off-the-shelf cell medicines in the respective fields of oncology, including solid tumors and blood cancers, for Editas Medicine and neurology, cardiology, and immunology for BlueRock." In the laboratory Editas has shown full engraftment and editing of the photo receptors within weeks in their EDIT101 research, so an early read-out on this proof of concept trial may come soon. The company also has 4 more ocular programs (3 named) in their partnership with Allergan/AbbVie that will rollout out in succession with one of them probably AMD.
|
|
|
Post by selluwud on Aug 6, 2020 11:35:28 GMT
Something's up in the gene editing(Cas9) sector. CRSP, EDIT & BEAM are all up considerably in pre-market, NTLA not as much. I recently got back in CRSP when it dipped. I should have held from the 30's I'd have a triple???
|
|
|
Post by JHam on Aug 6, 2020 14:21:45 GMT
Something's up in the gene editing(Cas9) sector. CRSP, EDIT & BEAM are all up considerably in pre-market, NTLA not as much. I recently got back in CRSP when it dipped. I should have held from the 30's I'd have a triple??? Did you find out what’s going on?
|
|
|
Post by selluwud on Aug 6, 2020 15:42:12 GMT
Nope, EDIT & BEAM held some of their pre-market gains & CRSP lost ground. Trading is weird these days.
|
|
|
Post by JHam on Aug 8, 2020 2:45:22 GMT
Nope, EDIT & BEAM held some of their pre-market gains & CRSP lost ground. Trading is weird these days.Truer words have never been spoken
|
|
|
Post by selluwud on Aug 8, 2020 12:07:17 GMT
Something's up in the gene editing(Cas9) sector. CRSP, EDIT & BEAM are all up considerably in pre-market, NTLA not as much. I recently got back in CRSP when it dipped. I should have held from the 30's I'd have a triple??? Did you find out what’s going on? I did read where it was suggested that EDIT & BEAM should merge, but it was just talk.
|
|